Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2007 1
2008 1
2009 2
2010 5
2011 3
2012 9
2013 8
2014 4
2015 15
2016 25
2017 21
2018 28
2019 24
2020 24
2021 20
2022 11
2023 8
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Results by year

Filters applied: . Clear all
Page 1
Reply to comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al.
Fukui R, Watanabe T, Morimoto K, Fujimoto Y, Nagahashi M, Ishikawa E, Hirota S, Miyoshi Y. Fukui R, et al. Among authors: nagahashi m. Breast Cancer. 2024 May;31(3):536-538. doi: 10.1007/s12282-024-01552-y. Epub 2024 Mar 4. Breast Cancer. 2024. PMID: 38433180 No abstract available.
Survival trends and patient characteristics between 2004 and 2016 for breast cancer in Japan based on the National Clinical Database-Breast Cancer Registry.
Iwamoto T, Kumamaru H, Niikura N, Sagara Y, Miyashita M, Konishi T, Sanuki N, Tanakura K, Nagahashi M, Hayashi N, Yoshida M, Watanabe C, Kinukawa N, Toi M, Saji S. Iwamoto T, et al. Among authors: nagahashi m. Breast Cancer. 2024 Mar;31(2):185-194. doi: 10.1007/s12282-024-01545-x. Epub 2024 Feb 6. Breast Cancer. 2024. PMID: 38319565
2020 Annual Report of National Clinical Database-Breast Cancer Registry: 10-year mortality of elderly breast cancer patients in Japan.
Sagara Y, Kumamaru H, Niikura N, Miyashita M, Konishi T, Iwamoto T, Sanuki N, Tanakura K, Nagahashi M, Hayashi N, Yoshida M, Kinukawa N, Watanabe C, Toi M, Saji S. Sagara Y, et al. Among authors: nagahashi m. Breast Cancer. 2024 Mar;31(2):179-184. doi: 10.1007/s12282-023-01532-8. Epub 2024 Jan 5. Breast Cancer. 2024. PMID: 38180641
Annual report of the Japanese Breast Cancer Registry for 2019.
Miyashita M, Kumamaru H, Niikura N, Sagara Y, Konishi T, Iwamoto T, Sanuki N, Tanakura K, Nagahashi M, Hayashi N, Yoshida M, Watanabe C, Kinukawa N, Toi M, Saji S. Miyashita M, et al. Among authors: nagahashi m. Breast Cancer. 2024 Jan;31(1):16-23. doi: 10.1007/s12282-023-01526-6. Epub 2023 Dec 4. Breast Cancer. 2024. PMID: 38044372
Intratumoral Tumor Infiltrating Lymphocytes (TILs) are Associated With Cell Proliferation and Better Survival But Not Always With Chemotherapy Response in Breast Cancer.
Wu R, Oshi M, Asaoka M, Yan L, Benesch MGK, Khoury T, Nagahashi M, Miyoshi Y, Endo I, Ishikawa T, Takabe K. Wu R, et al. Among authors: nagahashi m. Ann Surg. 2023 Oct 1;278(4):587-597. doi: 10.1097/SLA.0000000000005954. Epub 2023 Jun 15. Ann Surg. 2023. PMID: 37318852 Free PMC article.
An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers.
Fukui R, Watanabe T, Morimoto K, Fujimoto Y, Nagahashi M, Ishikawa E, Hirota S, Miyoshi Y. Fukui R, et al. Among authors: nagahashi m. Breast Cancer. 2023 Sep;30(5):703-713. doi: 10.1007/s12282-023-01462-5. Epub 2023 Apr 28. Breast Cancer. 2023. PMID: 37115435 Free PMC article.
201 results